Government-Owned Inventions; Availability for Licensing, 48569-48570 [E9-22974]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 183 / Wednesday, September 23, 2009 / Notices
funded entirely or partially by the
Children’s Bureau through grants,
contracts, and interagency agreements.
The cross-site evaluation uses a
mixed-method, longitudinal approach to
examine the ICs (funded in FY 2009)
and a new cohort of NRCs (funded in FY
2010). Proposed data collection methods
are a longitudinal telephone survey of
State child welfare directors (or their
designees) and Tribal Child Welfare/
Social Service Directors (or their
designees), a web-based survey of State
and Tribal T/TA recipients, and
aggregation of outputs from a web-based
technical assistance tracking system
(OneNet)that will be used by the five ICs
and 11 NRCs. A web-based survey will
be also administered to members of the
T/TA Network. Data collected through
these instruments will be used by the
Children’s Bureau to evaluate the
effectiveness of technical assistance
delivered to State, local, Tribal, and
other publicly administered or publicly
supported child welfare agencies and
48569
family and juvenile courts and the
overall functioning of the T/TA
Network.
Respondents: Respondents to two of
the survey instruments will be State and
Tribal governments. Respondents to the
third survey instrument will be private
institutions, including universities, notfor-profit organizations, and private
companies. Private institutions,
including universities and not-for-profit
organizations will be respondents to the
forms in the OneNet tracking system.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
mstockstill on DSKH9S0YB1PROD with NOTICES
Agency Results Survey .............................................................................
Training and Technical Assistance (T/TA) Activity Survey .......................
Web-Based Network Survey .....................................................................
OneNet Form: Implementation Project (IP) Description ............................
OneNet Form: IP Technical Assistance (TA) Activity ................................
OneNet Form: Implementation Center (IC) General TA Event .................
OneNet Form: IP Monthly Report ..............................................................
OneNet Form: National Resource Centers (NRC) TA Intake Form ..........
OneNet Form: NRC TA Work Plan ...........................................................
OneNet Form: NRC TA Close-Out ............................................................
OneNet Form: NRC TA Activity .................................................................
OneNet Form: NRC General TA Event .....................................................
Estimated Total Annual Burden
Hours: 2,231.51.
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
VerDate Nov<24>2008
17:06 Sep 22, 2009
Jkt 217001
Number of
responses per
respondent
74
600
30
5
5
5
5
11
11
11
11
11
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: September 18, 2009.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. E9–22897 Filed 9–22–09; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Average burden
hours per
response
1
1
1
5.40
280.80
4
62.40
45
45
45
528
36
1
0.25
0.25
0.50
0.33
0.33
0.17
0.13
0.20
0.08
0.20
0.25
Total burden
hours
74
150
7.50
13.50
463.32
6.60
53.04
64.35
99
39.60
1,161.60
99
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A Plasmid System for Monitoring
Double-Stranded DNA Breaks in the
Live Cell
Description of Technology: This
technology is useful for studying the
role of chromosomal breaks in cancer
and for drug and assay development
related to treating cancer. The
technology is a two-plasmid system for
inducing and monitoring individual
double-stranded DNA breaks in the
nuclei of live cells. The first plasmid,
lac-I-SceI-tet, which is stably transfected
into cells, has a rare 18 base pair
restriction endonuclease site called
ISceI. This site is flanked by an array of
256 copies of the lac-repressor binding
site and 96 copies of the tetracycline
response element. Plasmids expressing
tet and lac repressor proteins labeled in
a complementary fashion can be
cotransfected to visualize these arrays of
repressor binding sites. The second
E:\FR\FM\23SEN1.SGM
23SEN1
48570
Federal Register / Vol. 74, No. 183 / Wednesday, September 23, 2009 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
plasmid, RFP-I-SceI-GR, is a chimera
between the ISceI endonuclease and the
ligand binding domain of the
glucocorticoid receptor (GR) in frame
with red fluorescent protein (RFP). This
GR chimera will translocate from the
cytoplasm to the nucleus upon addition
of triamcinolone acetonide, leading to
rapid induction of a double-stranded
break between the lac and tet arrays.
Applications:
• Tool for drug studies relating to
DNA stability and repair.
• Tool to probe the role of nuclear
and DNA binding proteins in stability
and repair.
Inventors: Thomas A. Misteli and Evi
Soutoglou (NCI).
Related Publication: E Soutoglou, JF
Dorn, K Sengupta, M Jasin, A
Nussenzweig, T Ried, G Danuser, T
Misteli. Positional stability of single
double-strand breaks in mammalian
cells. Nat Cell Biol. 2007 Jun;9(6):675–
682.
Patent Status: HHS Reference No. E–
264–2009/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Steve Standley,
PhD; 301–435–4074; sstand@od.nih.gov.
Mouse Embryonic Stem Cell-Based
Functional Assay To Evaluate
Mutations in BRCA2
Description of Technology: Mutations
in breast cancer susceptibility genes
BRCA1 and BRCA2 have up to an 80
percent life time risk in developing
breast cancer. There are no ‘‘mutation
hot spots’’ and to date, more than 1,500
different mutations have been identified
in BRCA2. The absence of tumor cell
lines expressing various mutant BRCA2
alleles has hindered evaluations to
determine the functional differences
between different mutations.
A simple, versatile and reliable mouse
embryonic stem cell and bacterial
artificial chromosome based assay to
generate cell lines expressing mutant
human BRCA2 has been developed and
it has been used to classify 17 sequence
variants. Available for licensing are
wild-type and eleven mutant BRCA2
cell lines developed from this assay that
have either truncations or point
mutations. These cell lines may be used
to evaluate the effect of DNA damaging
agents, genotoxins and
chemotherapeutic efficacy.
Applications:
• Research tool to generate and study
BRCA2 mutations.
• Method to screen for
chemotherapeutics.
VerDate Nov<24>2008
17:06 Sep 22, 2009
Jkt 217001
• Method to evaluate DNA damaging
agents.
Advantages: Ready to use portfolio of
BRCA2 mutant cell lines to study
BRCA2 mutant functional analysis.
Market: An estimated 194,280 new
cases of breast cancer will be diagnosed
and may cause 40,610 deaths in the U.S.
in 2009.
Inventors: Shyam K. Sharan and
Sergey Kuznetsov (NCI).
Publication: SG Kuznetsov et al.
Mouse embryonic stem cell-based
functional assay to evaluate mutations
in BRCA2. Nat Med. 2008
Aug;14(8):875–881.
Patent Status: HHS Reference No. E–
261–2007/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Mouse Cancer Genetics Program,
Center for Cancer Research, National
Cancer Institute, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize mouse embryonic stem
cell lines suitable for functional analysis
of BRCA2 variants. Please contact John
D. Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Establishment of Two Cell Lines That
Stably Express Luciferase for In Vivo
Tracking
Description of Technology: Available
for licensing are two renal carcinoma
cell lines, 786-O(luc) and 786-O/VHL/
(luc) which both stably express
luciferase. 786-O(luc) lacks von HippelLandau (VHL) protein expression and it
has constitutively high expression of
hypoxia-inducible transcription factor2alpha (HIF-2alpha). The second stably
expresses VHL, a tumor suppressor, and
has minimal HIF-2alpha expression.
These cell lines can be tracked in vivo
and can be used to study VHLdependent and HIF-2alpha dependent
events such as tumorigenesis. VHL
mutations lead to the clinical
manifestations of von Hippel-Lindau
disease, a rare autosomal dominant
syndrome characterized by abnormal
growth of blood vessels in multiple
organs, including the brain and kidneys.
Applications: Model to study VHL
pathology.
Advantages: Cell lines that stably
express luciferase for in vivo tracking.
Benefits: Easy, ready to use positive
and negative VHL and HIF-2alpha cells
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
that stably express luciferase for in vivo
tests.
Market:
• Incidence of VHL syndrome is 1 in
38,951.
• HCC is the third leading cause of
cancer death worldwide.
• HCC is the fifth most common
cancer in the world.
• Post-operative five-year survival
rate of HCC patients is 30–40 percent.
Inventors: Leonard M. Neckers and W.
Marston Linehan (NCI).
Patent Status: HHS Reference No. E–
005–2007/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Urologic
Oncology Branch, is seeking statements
of capability or interest from parties
interested in collaborative research to
develop further uses for these two cell
lines that stably express luciferase for in
vivo tracking. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: September 17, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–22974 Filed 9–22–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 74, Number 183 (Wednesday, September 23, 2009)]
[Notices]
[Pages 48569-48570]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-22974]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Plasmid System for Monitoring Double-Stranded DNA Breaks in the Live
Cell
Description of Technology: This technology is useful for studying
the role of chromosomal breaks in cancer and for drug and assay
development related to treating cancer. The technology is a two-plasmid
system for inducing and monitoring individual double-stranded DNA
breaks in the nuclei of live cells. The first plasmid, lac-I-SceI-tet,
which is stably transfected into cells, has a rare 18 base pair
restriction endonuclease site called ISceI. This site is flanked by an
array of 256 copies of the lac-repressor binding site and 96 copies of
the tetracycline response element. Plasmids expressing tet and lac
repressor proteins labeled in a complementary fashion can be
cotransfected to visualize these arrays of repressor binding sites. The
second
[[Page 48570]]
plasmid, RFP-I-SceI-GR, is a chimera between the ISceI endonuclease and
the ligand binding domain of the glucocorticoid receptor (GR) in frame
with red fluorescent protein (RFP). This GR chimera will translocate
from the cytoplasm to the nucleus upon addition of triamcinolone
acetonide, leading to rapid induction of a double-stranded break
between the lac and tet arrays.
Applications:
Tool for drug studies relating to DNA stability and
repair.
Tool to probe the role of nuclear and DNA binding proteins
in stability and repair.
Inventors: Thomas A. Misteli and Evi Soutoglou (NCI).
Related Publication: E Soutoglou, JF Dorn, K Sengupta, M Jasin, A
Nussenzweig, T Ried, G Danuser, T Misteli. Positional stability of
single double-strand breaks in mammalian cells. Nat Cell Biol. 2007
Jun;9(6):675-682.
Patent Status: HHS Reference No. E-264-2009/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: This technology is available as a research tool
under a Biological Materials License.
Licensing Contact: Steve Standley, PhD; 301-435-4074;
sstand@od.nih.gov.
Mouse Embryonic Stem Cell-Based Functional Assay To Evaluate Mutations
in BRCA2
Description of Technology: Mutations in breast cancer
susceptibility genes BRCA1 and BRCA2 have up to an 80 percent life time
risk in developing breast cancer. There are no ``mutation hot spots''
and to date, more than 1,500 different mutations have been identified
in BRCA2. The absence of tumor cell lines expressing various mutant
BRCA2 alleles has hindered evaluations to determine the functional
differences between different mutations.
A simple, versatile and reliable mouse embryonic stem cell and
bacterial artificial chromosome based assay to generate cell lines
expressing mutant human BRCA2 has been developed and it has been used
to classify 17 sequence variants. Available for licensing are wild-type
and eleven mutant BRCA2 cell lines developed from this assay that have
either truncations or point mutations. These cell lines may be used to
evaluate the effect of DNA damaging agents, genotoxins and
chemotherapeutic efficacy.
Applications:
Research tool to generate and study BRCA2 mutations.
Method to screen for chemotherapeutics.
Method to evaluate DNA damaging agents.
Advantages: Ready to use portfolio of BRCA2 mutant cell lines to
study BRCA2 mutant functional analysis.
Market: An estimated 194,280 new cases of breast cancer will be
diagnosed and may cause 40,610 deaths in the U.S. in 2009.
Inventors: Shyam K. Sharan and Sergey Kuznetsov (NCI).
Publication: SG Kuznetsov et al. Mouse embryonic stem cell-based
functional assay to evaluate mutations in BRCA2. Nat Med. 2008
Aug;14(8):875-881.
Patent Status: HHS Reference No. E-261-2007/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The Mouse Cancer Genetics
Program, Center for Cancer Research, National Cancer Institute, is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
mouse embryonic stem cell lines suitable for functional analysis of
BRCA2 variants. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Establishment of Two Cell Lines That Stably Express Luciferase for In
Vivo Tracking
Description of Technology: Available for licensing are two renal
carcinoma cell lines, 786-O(luc) and 786-O/VHL/(luc) which both stably
express luciferase. 786-O(luc) lacks von Hippel-Landau (VHL) protein
expression and it has constitutively high expression of hypoxia-
inducible transcription factor-2alpha (HIF-2alpha). The second stably
expresses VHL, a tumor suppressor, and has minimal HIF-2alpha
expression. These cell lines can be tracked in vivo and can be used to
study VHL-dependent and HIF-2alpha dependent events such as
tumorigenesis. VHL mutations lead to the clinical manifestations of von
Hippel-Lindau disease, a rare autosomal dominant syndrome characterized
by abnormal growth of blood vessels in multiple organs, including the
brain and kidneys.
Applications: Model to study VHL pathology.
Advantages: Cell lines that stably express luciferase for in vivo
tracking.
Benefits: Easy, ready to use positive and negative VHL and HIF-
2alpha cells that stably express luciferase for in vivo tests.
Market:
Incidence of VHL syndrome is 1 in 38,951.
HCC is the third leading cause of cancer death worldwide.
HCC is the fifth most common cancer in the world.
Post-operative five-year survival rate of HCC patients is
30-40 percent.
Inventors: Leonard M. Neckers and W. Marston Linehan (NCI).
Patent Status: HHS Reference No. E-005-2007/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Urologic Oncology Branch, is seeking statements of capability or
interest from parties interested in collaborative research to develop
further uses for these two cell lines that stably express luciferase
for in vivo tracking. Please contact John D. Hewes, Ph.D. at 301-435-
3121 or hewesj@mail.nih.gov for more information.
Dated: September 17, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E9-22974 Filed 9-22-09; 8:45 am]
BILLING CODE 4140-01-P
